Gastroesophageal Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Gastroesophageal Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 5 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4568.T | Daiichi Sankyo | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel | Phase 3 | Active, not recruiting | 2026-08-31 | in 11 d | 2026-05-27 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | 2026-09-28 | in 39 d | 2026-06-17 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | 2026-10-01 | in 42 d | 2026-06-23 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | 2026-11-17 | in 89 d | 2026-07-29 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| PFE | Pfizer | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-03-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Gastroesophageal Cancer
most recently updated first78 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaNCT07069712Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Phase 2 | Recruiting | Drug: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinate | Gastroesophageal Adenocarcinoma | 100 | 2025-07-17 | 2027-11-03 | in 440 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerNCT07392892Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator | Phase 2/3 | Recruiting | Biological: PF-08634404, Nivolumab · Drug: Chemotherapy | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 840 | 2026-05-14 | 2031-07-22 | in 1,797 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerNCT06731478Progression Free Survival (PFS) | Phase 3 | Recruiting | Drug: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy | Gastric Cancer, Gastroesophageal Junction Cancer | 726 | 2025-02-27 | 2028-06-01 | in 651 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07043400Model-Predicted Steady State Trough Concentration (Ctrough) of Tislelizumab | Phase 3 | Recruiting | Drug: Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 351 | 2025-08-27 | 2027-10-30 | in 436 d | 2026-08-07 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| AZN | AstraZeneca | — | Study for AZD4360 in Participants With Advanced Solid TumoursNCT06921928Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360 | Phase 1/2 | Active, not recruiting | Drug: AZD4360 | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 31 | 2025-04-29 | 2027-03-31 | in 223 d | 2026-07-31 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 Study of the Safety and Tolerability of CTX-10726NCT07419841Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses | Phase 1 | Recruiting | Drug: CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | 2026-05-28 | 2028-04-01 | in 590 d | 2026-07-31 |
| AMGN | Amgen | $229.9B | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.NCT05322577Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Bemarituzumab, CAPOX, SOX, Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 72 | 2022-05-17 | 2025-11-21actual | — | 2026-07-29 |
| AZN | AstraZeneca | — | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | Drug: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 226 | 2023-12-13 | 2026-11-17 | in 89 d | 2026-07-29 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2023-11-20 | 2029-09-12 | in 1,119 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892Number of participants with dose limiting toxicities (DLTs) in dose escalation phase | Phase 2 | Active, not recruiting | Drug: disitamab vedotin, tucatinib | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 54 | 2024-05-20 | 2029-07-28 | in 1,073 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNCT06628310Progression-Free Survival (PFS) as Assessed by Investigator | Phase 2 | Active, not recruiting | Drug: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 185 | 2024-12-13 | Oct 2030 | ≤ 1,533 d | 2026-07-21 |
| AMGN | Amgen | $229.9B | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.NCT05111626Part 1: Number of Participants Who Experienced DLTs | Phase 3 | Terminatedsponsor's stated reason: Study was terminated by sponsor | Drug: Bemarituzumab, Nivolumab, Chemotherapy · Other: Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 515 | 2022-03-14 | 2025-10-14actual | — | 2026-07-17 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147Progression-free survival (PFS) by BICR | Phase 3 | Active, not recruiting | Drug: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 920 | 2021-12-02 | 2026-07-31 | — | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| GILD | Gilead Sciences | $177.9B | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasNCT07546812Objective Response Rate (ORR) | Phase 2 | Recruiting | Drug: Denikitug, Nivolumab, Ramucirumab, Paclitaxel | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 120 | Jul 2026 | Jan 2030 | ≤ 1,260 d | 2026-07-10 |
| AZN | AstraZeneca | — | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2NCT06346392Progression Free Survival (PFS) in all randomized participants | Phase 3 | Active, not recruiting | Drug: AZD0901, AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib | Gastric Cancer, Gastroesophageal Junction Cancer | 594 | 2024-03-04 | 2026-05-31actual | — | 2026-07-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| AZN | AstraZeneca | — | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2NCT07431281Progression Free Survival (PFS) (Cohort 1 and Cohort 2) | Phase 3 | Recruiting | Drug: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | 2026-02-03 | 2029-08-16 | in 1,092 d | 2026-07-01 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerNCT06038578Progression free Survival (PFS) | Phase 2 | Recruiting | Biological: TRK-950 · Drug: Ramucirumab, Paclitaxel | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 146 | 2023-10-04 | 2026-06-30 | — | 2026-06-23 |
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | Drug: Nivolumab | Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 726 | 2025-10-09 | 2026-10-01 | in 42 d | 2026-06-23 |
| AZN | AstraZeneca | — | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: AZD0901 | Gastric Cancer, Gastroesophageal Junction Cancer | 33 | 2025-08-29 | 2026-09-28 | in 39 d | 2026-06-17 |
| AZN | AstraZeneca | — | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerNCT06764875Progression free survival (PFS) | Phase 3 | Recruiting | Drug: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin | HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 840 | 2025-03-01 | 2029-04-27 | in 981 d | 2026-06-16 |
| 4568.T | Daiichi Sankyo | $31.7B | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel | Phase 3 | Active, not recruiting | Drug: Trastuzumab deruxtecan, Ramucirumab, Paclitaxel | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 490 | 2021-05-21 | 2026-08-31 | in 11 d | 2026-05-27 |
| AMGN | Amgen | $229.9B | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05052801Overall Survival | Phase 3 | Completed | Drug: Bemarituzumab, mFOLFOX6, Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 547 | 2022-03-07 | 2025-06-20actual | — | 2026-05-27 |
| BMY | Bristol-Myers Squibb | $134.9B | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceNCT06504615observationalOverall survival (OS) | — | Active, not recruiting | Drug: nivolumab + chemotherapy | Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) | 208 | 2024-12-10 | 2028-08-31 | in 742 d | 2026-04-03 |
| PFE | Pfizer | $155.3B | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | Drug: Tucatinib | Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 25 | 2022-06-29 | 2026-12-31 | in 133 d | 2026-03-12 |
| PFE | Pfizer | $155.3B | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsNCT05233436Number of participants with Dose-limiting toxicities (DLTs) in Dose Escalation (Part 1) | Phase 1 | Terminatedsponsor's stated reason: Study terminated based on internal business considerations and was not based on safety reasons | Drug: PF-07265028 · Biological: Sasanlimab | Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas | 21 | 2022-02-24 | 2023-10-16actual | — | 2026-02-19 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645Dose Limiting toxicity (DLT) of PRT7732 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT7732 | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 42 | 2024-11-04 | 2026-01-28actual | — | 2026-02-02 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299Number of Subjects Experiencing Dose-limiting Toxicity | Phase 1 | Recruiting | Drug: KK2269, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer | 101 | 2024-01-18 | Mar 2029 | ≤ 954 d | 2026-01-28 |
| BOLT | Bolt Biotherapeutics, Inc. | $6M | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal CancerNCT06921837Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 | Phase 1/2 | Recruiting | Drug: BDC-4182 | Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | 122 | 2025-05-26 | May 2027 | ≤ 284 d | 2026-01-27 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: sigvotatug vedotin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 6 | 2024-08-21 | 2025-11-18actual | — | 2025-12-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction CancerNCT06452329observationalTime to progression (TTP) | — | Completed | Drug: Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 260 | 2024-02-28 | 2025-07-29actual | — | 2025-12-04 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabNCT05029882Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Trifluridine/Tipiracil, Bevacizumab | Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer | 520 | 2021-10-13 | Nov 2027 | ≤ 467 d | 2025-10-29 |
| AZN | AstraZeneca | — | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerNCT04931654Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE) | Phase 1/2 | Active, not recruiting | Drug: AZD7789 | Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer | 136 | 2021-09-28 | 2024-12-04actual | — | 2025-10-09 |
| TPST | Tempest Therapeutics | $16M | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab | Phase 1 | Completed | Drug: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab | Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation | 89 | 2020-05-06 | 2024-09-25actual | — | 2025-09-12 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaNCT06585501observationalPercentage of patients receiving first-line, second-line, and third-line anti-tumor regimens | — | Completed | Other: No drug | Gastric Cancer, Gastroesophageal Junction Cancer | 805 | 2024-08-15 | 2025-07-30actual | — | 2025-08-21 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| INCY | Incyte Corporation | $24.7B | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsNCT03314935results2023-12-07Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Completed | Drug: INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel | Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors | 149 | 2017-11-21 | 2022-11-28actual | — | 2025-08-12 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerNCT02872116results2022-06-28Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 | Phase 3 | Completed | Drug: Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 2,031 | 2016-10-12 | 2020-05-27actual | — | 2025-08-07 |
| ALXO | ALX Oncology Inc. | $288M | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127Phase 2 | Phase 2/3 | Active, not recruiting | Drug: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 127 | 2022-01-15 | 2024-05-24actual | — | 2025-08-07 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205Safety: incidence and severity of adverse events and serious adverse events | Phase 1/2 | Withdrawnsponsor's stated reason: Corporate business decision | Drug: AB-201, Cyclophosphamide, Fludarabine | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 0 | 2023-08-01 | Apr 2027 | ≤ 253 d | 2025-07-30 |
| MGNX | MacroGenics | $261M | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364results2025-04-22Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0 | Phase 2/3 | Completed | Biological: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab · Other: Chemotherapy | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | 82 | 2019-09-30 | 2024-01-15actual | — | 2025-06-08 |
| BMY | Bristol-Myers Squibb | $134.9B | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction CancerNCT06499298observationalParticipant disease-free survival (DFS) | — | Completed | Drug: Nivolumab | Esophageal Cancer, Gastroesophageal Junction Cancer | 64 | 2024-12-03 | 2025-04-16actual | — | 2025-05-31 |
| STTK | Shattuck Labs, Inc. | $748M | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252 | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2019-03-26 | 2023-05-04actual | — | 2025-04-02 |
| LLY | Eli Lilly and Company | $1.15T | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceNCT02307812expanded access | — | Approved for marketing | Drug: Ramucirumab, Paclitaxel | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | — | — | — | — | 2025-01-09 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaNCT04281576Objective response rate | Not applicable | Completed | Device: NovoTTF-100L(P) · Drug: Oxaliplatin, Capecitabine, Trastuzumab | Gastric Cancer, GastroEsophageal Cancer | 28 | 2019-12-19 | 2024-06-07actual | — | 2024-11-14 |
| AZN | AstraZeneca | — | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursNCT04504669Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs | Phase 1 | Completed | Drug: AZD8701 · Biological: Durvalumab | Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours | 60 | 2020-08-18 | 2024-10-07actual | — | 2024-11-05 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsNCT04683939results2024-10-02Occurrence of Treatment-emergent Adverse Events (TEAEs) Within a Patient Including Grade ≥ 3, Serious, Fatal TEAE by Relationship | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT141, Nab-paclitaxel, Gemcitabine | Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer | 13 | 2022-01-18 | 2023-07-24actual | — | 2024-10-02 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal CancerNCT05780736observationalDisease-free Survival (DFS) | — | Terminatedsponsor's stated reason: A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study. | — | Esophageal Carcinoma, Gastroesophageal Junction Carcinoma | 33 | 2023-08-04 | 2024-08-23actual | — | 2024-09-25 |
| LIANY | LianBio LLC | $5M | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaNCT06206278Objective response rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Business Reason | Drug: Infigratinib | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 6 | 2023-10-19 | 2024-05-31actual | — | 2024-08-14 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2018-07-24 | 2021-08-18actual | — | 2024-05-24 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal MalignanciesNCT03720678Incidence of Adverse Events (AEs) | Phase 1 | Completed | Drug: etrumadenant, mFOLFOX | GastroEsophageal Cancer, Colorectal Cancer | 44 | 2018-11-18 | 2021-01-27actual | — | 2024-05-24 |
| FATE | Fate Therapeutics | $307M | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05395052Determine the Recommended Phase 2 Dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Drug: FT536, Cyclophosphamide, Fludarabine, IL-2, IL-2 · Combination product: Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab | Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer | 5 | 2022-05-31 | 2023-08-11actual | — | 2023-09-21 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| GOSS | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2019-08-13 | 2022-04-11actual | — | 2022-08-18 |
| LIANY | LianBio LLC | $5M | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsNCT05019794Objective Response Rate (ORR) | Phase 2 | Unknown status | Drug: Infigratinib | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 80 | 2020-05-13 | 2022-12-30 | — | 2022-06-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerNCT02898077results2021-08-03Progression Free Survival (PFS) | Phase 3 | Completed | Drug: Ramucirumab, Paclitaxel, Placebo | Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 440 | 2017-03-02 | 2020-06-30actual | — | 2022-06-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction AdenocarcinomaNCT02539225results2019-02-15Progression Free Survival (PFS) | Phase 2 | Completed | Drug: Ramucirumab, Placebo, S-1, Oxaliplatin, Paclitaxel | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 191 | 2015-10-05 | 2017-10-25actual | — | 2022-03-08 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2018-09-24 | 2021-08-18actual | — | 2021-11-15 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach CancerNCT02314117results2018-05-02Progression-free Survival (PFS) | Phase 3 | Completed | Drug: Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 645 | 2015-01-20 | 2017-01-17actual | — | 2021-08-26 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) ExpressionNCT03125200results2019-08-28Number of Participants Who Experienced Dose-Limiting Toxicities | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: ADCT-502 | Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer | 21 | 2017-05-18 | 2018-04-05actual | — | 2021-02-01 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesNCT02572687Number of Participants with Dose Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Ramucirumab, MEDI4736 | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 85 | 2016-02-19 | 2018-03-27actual | — | 2021-01-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerNCT02082210results2020-12-19Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: Emibetuzumab, Ramucirumab | Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer | 97 | 2014-03-07 | 2017-12-05actual | — | 2020-12-19 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaNCT02864381results2020-09-18Objective Response Rate (ORR) | Phase 2 | Completed | Drug: Andecaliximab, Nivolumab | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 144 | 2016-09-01 | 2017-11-08actual | — | 2020-09-18 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) CancerNCT02443883results2018-03-13Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab | Phase 2 | Completed | Drug: Ramucirumab | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 164 | 2015-07-07 | 2016-11-18actual | — | 2020-06-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric CancerNCT02514551results2018-12-19Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ | Phase 2 | Completed | Drug: Ramucirumab, Paclitaxel | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 245 | 2015-10-12 | 2017-10-27actual | — | 2020-06-17 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNCT03704077Overall response rate (ORR) | Phase 2 | Withdrawnsponsor's stated reason: Replaced it with another clinical trial | Biological: Relatlimab + Nivolumab, Nivolumab · Drug: Paclitaxel, Ramucirumab | Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction | 0 | 2019-10-31 | 2022-02-27 | — | 2020-05-19 |
| AZN | AstraZeneca | — | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursNCT02586987Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events | Phase 1 | Completed | Drug: Selumetinib, MEDI4736, Tremelimumab | Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer | 58 | 2015-12-28 | 2018-07-25actual | — | 2019-11-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Gastroesophageal Cancer is matched — 10 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Cancer
- GastroEsophageal Cancer
- Gastroesophageal Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Cancer (GC)
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Gastro-esophageal Junction Adenocarcinoma
- Gastroesophageal Junction
- Gastroesophageal Junction Carcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Gastroesophageal Cancer” (a text search, wider than this page)